Search results
Showing 1066 to 1080 of 1516 results for patients and public
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux. This involves inserting hydrogel implants into the wall of the oesophagus to narrow the entrance to the stomach and help prevent reflux.
View recommendations for HTG142Show all sections
Sections for HTG142
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
podcasts bring you the real life experiences of people working within the NHS, public health and social care. News News articles...
Give patients clear information to support shared decision making , including NICE's information for the public . Ensure...
MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)
Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.
View recommendations for HTG110Show all sections
Sections for HTG110
Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.
View recommendations for HTG99Show all sections
Awaiting development Reference number: GID-TA11019 Expected publication date: TBC